Dr Reddy's To Acquire Mayne Pharma’s US Generic Prescription Product Portfolio

Pharma major Dr Reddy's Laboratories on Monday (27 February) announced that it has entered into a definitive agreement to acquire the US generic prescription product portfolio of Australia-based Mayne Pharma Group Limited.

The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women’s health, the company said in a statement.

For the financial period ended 30 June 2022, Mayne Pharma reported total revenue of $111 million for the acquired portfolio, the company said.

Approved high-value products include a hormonal vaginal ring, a birth control pill and a cardiovascular product, the company said.

Under the terms of the agreement, Dr Reddy’s will acquire the portfolio for an upfront payment of approximately $90 million in cash, contingent payments of up to $15 million, consideration towards inventory and credits for certain accrued channel liabilities to be determined on the closing date.

The closing of the transaction is subject to satisfactory completion of customary closing conditions including the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act), as amended.

The acquisition will complement Dr Reddy’s US retail prescription pharmaceutical business with limited competition products, teh company said.

It also supports Dr. Reddy’s efforts to accelerate and expand affordable medications for patients, it

Marc Kikuchi, chief executive officer of Dr Reddy's in North America said, “This important acquisition provides our North America organization with a significant foothold in the women’s health space. The acquisition is in line with our stated strategy to enhance our portfolio in our chosen growth markets. We are well-positioned to successfully integrate the portfolio and grow the business.”

Dr Reddy’s CEO Erez Israeli said, “The US has always been an important market for us. The portfolio of products acquired from Mayne Pharma is a strategic fit with our growth objectives. The portfolio includes some high entry-barrier products. It also complements our existing portfolio by introducing products focused on women’s health".